Furthermore, the effects of GB4-BPL@siCXCR2/pPTEN on antitumoral contributors to cancer immunotherapy, including M1-like macrophages, NK cells, and CD8+ T cells, were also evaluated. This evidence concerns the gene CD8A and cancer.